|本期目录/Table of Contents|

[1]马传勇,陈梅珠,查志伟.抗血管内皮生长因子联合Ahmed引流阀植入术治疗新生血管性青光眼[J].医学研究与战创伤救治(原医学研究生学报),2018,20(02):118-121.[doi:10.3969/j.issn.1672-271X.2018.02.002]
　MA Chuan-yong,CHEN Mei-zhu,ZHA Zhi-wei.Anti-VEGF combined Ahmed drainage valve implantation for neovascular glaucoma[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(02):118-121.[doi:10.3969/j.issn.1672-271X.2018.02.002]
点击复制

抗血管内皮生长因子联合Ahmed引流阀植入术治疗新生血管性青光眼()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第20卷
期数:
2018年02期
页码:
118-121
栏目:
出版日期:
2018-03-20

文章信息/Info

Title:
Anti-VEGF combined Ahmed drainage valve implantation for neovascular glaucoma
作者:
马传勇; 陈梅珠; 查志伟
作者单位：350025福州，南京军区福州总医院眼科（马传勇、陈梅珠、查志伟）
Author(s):
MA Chuan-yong; CHEN Mei-zhu; ZHA Zhi-wei
（Department of Ophtalmology，Fuzhou General Hospital of Nanjing Military Region,PLA, Fuzhou 350025，Fujian,China）
关键词:
新生血管性青光眼;  抗血管内皮生长因子; Ahmed青光眼引流阀植入术; 视网膜激光光凝术; 眼压
Keywords:
neovascular glaucoma;  anti-VEGF;  Ahmed glaucoma valve implantation;  endolaser photocoagulation;  intraocular pressure
分类号:
R775
DOI:
10.3969/j.issn.1672-271X.2018.02.002
文献标志码:
A
摘要:
目的 观察玻璃体腔注射抗血管内皮生长因子（VEGF）及Ahmed青光眼引流阀植入治疗新生血管性青光眼（NVG）患者的远期疗效及并发症。方法 回顾性分析福州总医院收治的NVG患者19例20眼，13眼行玻璃体腔注射抗VEGF及Ahmed青光眼引流阀植入联合玻璃体切除术（PPV），术中行全视网膜光凝术（PRP）；另7眼行玻璃体腔注射抗VEGF及Ahmed青光眼引流阀植入术，术后根据眼底血管荧光造影情况对血管无灌注区行激光光凝术。观察19例患者术中和术后并发症，分别观察术后1周、1个月、3个月、6个月、12个月时的眼压、视力、虹膜新生血管生长及降眼压药物使用情况。结果 20眼术前平均眼压值为（45.00±3.60）mmHg，术后1周、1个月、3个月、6个月、12个月随访时的平均眼压值分别为（12.00±2.21）、（15.20±1.79）、（16.52±1.35）、（17.28±3.17）、（19.00±2.31）mmHg，治疗后各随访时间点眼压较治疗前差异具有统计学意义(P＜0.05) 。结论 玻璃体腔内注射抗VEGF 后植入Ahmed青光眼引流阀联合视网膜激光光凝术对新生血管性青光眼治疗有效，并能有效控制患者的眼压。
Abstract:
Objective To evaluate the effect of intravitreal anti-VEGF injection and Ahmed glaucoma valve (AGV) implantation in patients with neovascular glaucoma (NVG) eyes.Methods This retrospective study included 19 NVG patients (20 eyes) who underwent AGV implantation. Panretinal laser photocoagulation was performed for 13 eyes with NVG who underwent intravitreal anti-VEGF injection and Ahmed glaucoma valve (AGV) implantation. The other patients underwent fluorescein angiography of the fundus and retinal laser photocoagulation on the non-perfusion area after Ahmed glaucoma valve (AGV) implantation and intravitreal injection VEGF. Results Mean intraocular pressure (IOPs) before treatment was (45.00±3.60) mmHg. Mean intraocular pressure after treatment was (12.00±2.21), (15.20±1.79), (16.52±1.35), (17.28±3.17), (19.00±2.31) mmHg in 1week and 1, 3, 6, 12 months. The IOPs at every follow-up time was significantly different from that before treatment (P＜0.05).Conclusion Combining Ahmed glaucoma valve (AGV) implantation with retinal laser photocoagulation after intravitreal anti-VEGF injection may achieve great effect on patients with NVG.

参考文献/References:

[1]Havens SJ, Gulati V. Neovascular glaucoma[J]. Dev Ophthalmol，2016，55: 196-204.
[2]李裕钦,薛雨顺,车选义,等.新生血管性青光眼的手术治疗[J].眼科新进展,2005,25(4):358,377.
[3]Kwon J, Sung KR. Effect ofpreoperative intravitreal bevacizumab on the surgical outcome of neovascular glaucoma at different stages[J]. J Ophthalmol, 2017: 7672485. DOI:10.1155/2017/7672485.
[4]Nakano S, Nakamuro T, Yokoyama K, et al. Prognosticfactor analysis of intraocular pressure with neovascular glaucoma[J]. J Ophthalmol, 2016: 1205895. DOI: 10.1155/2016/1205895
[5]Shen X, Chen Y, Wang Y, et al. Intravitrealranibizumab injection as an adjuvant in the treatment of neovascular glaucoma accompanied by vitreous hemorrhage after diabetic vitrectomy[J]. J Ophthalmol, 2016: 4108490. DOI: 10.1155/2016/4108490.
[6]Lüke J, Nassar K, Lüke M, et al. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma-results from a prospective interventional case series[J]. Graefes Arch Clin Exp Ophthalmol,2013,251(10): 2403-2413.
[7]葛坚,王宁利.眼科学[M].3版.北京：人民卫生出版社，2015：262-263.
[8]Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases[J].Ophthalmology,2008,115(9): 1571-1580.
[9]Sahyoun M, Azar G, Khoueir Z, et al. Long-term results of Ahmed glaucoma valve in association with intravitreal bevacizumab in neovascular glaucoma[J]. J Glaucoma,2015,24(5): 383-388.
[10]Arcieri ES, Paula JS, Jorge R, et al. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up[J]. Acta Ophthalmol,2015,93(1): e1-6.
[11]赵明威. 新生血管性青光眼治疗面临的临床问题与思考[J]. 中华实验眼科杂志,2016,34(7): 577-579.
[12]Zhao X, Wang Z, Yang X. Management of neovascular glaucoma with intravitreal ranibizumab, panretinal photocoagulation, and subsequent 5-fluorouracil augmented trabeculectomy: A case report[J]. Medicine (Baltimore)，2017,96(25):e7221.
[13]杨智,王昕华,李若溪.新生血管性青光眼不同治疗方法疗效对比分析[J].国际眼科杂志，2012，12（1）：104-106.
[14]梁勇,赵明威,潘中婷，等.新生血管性青光眼治疗策略的初步探讨[J].中国实用眼科杂志,2011,29(3):231-235.
[15]王婷,秦虹,于磊，等.康柏西普玻璃体腔注射联合Ahmed青光眼阀植入治疗新生血管性青光眼效果分析[J].中国实用眼科杂志,2016,34(5):419-423.

相似文献/References:

备注/Memo

备注/Memo:
基金项目：福建省科技计划项目（2016Y0067）
更新日期/Last Update: 2018-03-20